2024 veterinary news in review: #10

Photo: Sap/Adobe Stock

The dvm360 editorial team is counting down our Top 20 news stories and articles of the year, from January 1, 2024, to November 15, 2024. Rank was determined by measurable audience interest and engagement.

A spotlight is shining on 1 article each day through New Year’s Eve, when the No. 1 dvm360 story of the year will be shared. The following article is No. 10 on this list:

First RNA-particle vaccination for canine influenza receives USDA approval

written by Caitlin McCafferty, Editor

Originally published June 25, 2024

Merck Animal Health announced that its latest product, NOBIVAC NXT Canine Flu H3N2, has received approval from the US Department of Agriculture (USDA). According to an organizational release,¹ NOBIVAC NXT Canine Flu H3N2 is a vaccination that leverages RNA-particle technology to allow a precise immune response to protect against a range of bacterial and viral pathogens.

"On behalf of Merck Animal Health and our NOBIVAC brand, we are beyond proud to introduce our latest vaccine using ‘NXT-level’ technology. This is a groundbreaking advancement in our vaccine pipeline designed to meet the evolving needs of veterinarians and pet owners alike,” said Christine Royal, DVM, vice president, companion animal and equine business unit, Merck Animal Health.¹ “With over 70 years of innovation and commitment to animal health, our new NOBIVAC NXT technology will continue to lead the way in providing breakthrough solutions for the prevention of disease in animals.”

RELATED: 2024 veterinary news in review: #11

NOBIVAC NXT Canine Flu H3N2 is currently the first and only canine influenza vaccination to be built on the company’s RNA-particle platform to protect pets against the most prevalent canine influenza spreading across the United States. The vaccination is a nonadjuvanted, low-volume 0.5 mL dose that utilizes the immune system’s natural ability to generate a response without compromising the safety or comfort of the pet.¹ The vaccination is indicated for healthy dogs 8 weeks or older against canine influenza H3N2.

According to the American Veterinary Medicinal Association, canine influenza is a highly contagious respiratory disease caused by 2 type A influenza virus. Canine patients of any age, breed, sex, or health status are at risk and infections can occur anytime during the year.²

For more on this story, view the full article here: https://www.dvm360.com/view/first-rna-particle-vaccination-for-canine-influenza-receives-usda-approval